Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 18 04:00PM ET
32.46
Dollar change
+0.01
Percentage change
0.03
%
IndexRUT P/E- EPS (ttm)-0.99 Insider Own3.45% Shs Outstand113.86M Perf Week0.06%
Market Cap3.73B Forward P/E- EPS next Y-0.95 Insider Trans-8.18% Shs Float110.83M Perf Month0.81%
Income-105.37M PEG- EPS next Q-0.32 Inst Own99.49% Short Float5.28% Perf Quarter50.00%
Sales31.07M P/S119.91 EPS this Y-45.94% Inst Trans-0.91% Short Ratio1.57 Perf Half Y96.49%
Book/sh2.57 P/B12.65 EPS next Y34.54% ROA-36.55% Short Interest5.85M Perf Year255.14%
Cash/sh3.43 P/C9.45 EPS next 5Y- ROE-64.17% 52W Range7.26 - 32.47 Perf YTD37.43%
Dividend Est.- P/FCF- EPS past 5Y4.59% ROI-26.56% 52W High-0.03% Beta0.32
Dividend TTM- Quick Ratio10.96 Sales past 5Y0.00% Gross Margin97.81% 52W Low347.05% ATR (14)0.31
Dividend Ex-Date- Current Ratio10.96 EPS Y/Y TTM17.84% Oper. Margin-327.23% RSI (14)81.11 Volatility0.10% 0.21%
Employees101 Debt/Eq0.39 Sales Y/Y TTM- Profit Margin-339.10% Recom2.83 Target Price30.61
Option/ShortYes / Yes LT Debt/Eq0.36 EPS Q/Q-21.93% Payout- Rel Volume0.89 Prev Close32.45
Sales Surprise-86.59% EPS Surprise-12.58% Sales Q/Q- EarningsFeb 28 AMC Avg Volume3.74M Price32.46
SMA200.52% SMA5016.46% SMA20080.81% Trades Volume3,322,803 Change0.03%
Date Action Analyst Rating Change Price Target Change
Feb-13-24Downgrade Raymond James Outperform → Mkt Perform
Aug-14-23Initiated UBS Buy $18
Aug-11-23Initiated Guggenheim Buy $20
Apr-05-23Initiated William Blair Outperform
Mar-09-23Initiated BTIG Research Buy $15
Apr-11-22Resumed Cantor Fitzgerald Overweight $9
Aug-04-20Reiterated H.C. Wainwright Buy $9 → $13
Jul-31-20Initiated Piper Sandler Overweight $12
May-26-20Upgrade H.C. Wainwright Neutral → Buy $9
May-12-20Upgrade SVB Leerink Mkt Perform → Outperform $6
Mar-04-24 08:00AM
Feb-28-24 06:10PM
04:45PM
Feb-21-24 05:43PM
Feb-20-24 04:05PM
03:01AM Loading…
Feb-15-24 03:01AM
Feb-12-24 04:15PM
01:43PM
01:27PM
12:34PM
12:27PM
12:03PM
09:57AM
09:45AM
09:18AM
08:45AM Loading…
08:45AM
08:44AM
08:42AM
08:38AM
08:33AM
08:30AM
Jan-31-24 08:00AM
Jan-22-24 11:47PM
Jan-17-24 05:01AM
Jan-16-24 04:28PM
Jan-12-24 05:02AM
Jan-03-24 08:00AM
Jan-02-24 08:00AM
Dec-28-23 12:15PM
Dec-19-23 01:01PM
04:05PM Loading…
Dec-18-23 04:05PM
Dec-16-23 11:01AM
Dec-15-23 08:00AM
Dec-01-23 09:30AM
Nov-18-23 01:03AM
Nov-17-23 04:15PM
Nov-15-23 11:03PM
Nov-13-23 08:00AM
Nov-09-23 03:27PM
Nov-08-23 09:55AM
Nov-07-23 04:04PM
Nov-06-23 08:00AM
Nov-01-23 08:00AM
Oct-31-23 04:05PM
Oct-26-23 09:40AM
Oct-25-23 08:50AM
Oct-23-23 06:16PM
04:05PM
08:00AM
Oct-19-23 05:01AM
Oct-18-23 08:00AM
Oct-16-23 04:05PM
Oct-10-23 11:01PM
Sep-27-23 09:24PM
Sep-21-23 04:39PM
08:00AM
Sep-20-23 01:01AM
Sep-15-23 08:00AM
Sep-14-23 04:57PM
Sep-12-23 05:37PM
Sep-11-23 10:15PM
06:31PM
06:00AM
Sep-08-23 04:49PM
01:12PM
11:59AM
Sep-07-23 07:00AM
Sep-06-23 04:05PM
Aug-28-23 04:29PM
Aug-12-23 08:48AM
Aug-11-23 09:36AM
Aug-10-23 04:04PM
08:00AM
Aug-03-23 04:05PM
Jul-17-23 08:50AM
Jun-30-23 11:50AM
Jun-24-23 03:19PM
Jun-21-23 03:00AM
Jun-07-23 02:00AM
May-19-23 05:59PM
May-16-23 11:06AM
08:50AM
May-15-23 04:04PM
May-10-23 08:00AM
May-09-23 08:00AM
Apr-28-23 07:00AM
Apr-26-23 10:01AM
Apr-21-23 08:00AM
Apr-17-23 08:00AM
Mar-29-23 08:50AM
Mar-28-23 09:55AM
Mar-20-23 09:04PM
Mar-18-23 08:31AM
Mar-16-23 04:04PM
Mar-09-23 04:05PM
Mar-01-23 08:00AM
Feb-06-23 08:00AM
Jan-30-23 08:00AM
Jan-24-23 07:00AM
Jan-23-23 04:11PM
CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. Its products pipeline includes Seladelpar, MBX-2982, CB-0406, and CB-001. The company was founded on October 5, 1988 and is headquartered in Newark, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Shah SujalChief Executive OfficerMar 13 '24Option Exercise4.72139,119655,959406,670Mar 15 04:03 PM
Quinlan Paul TGeneral CounselMar 13 '24Option Exercise7.8941,824329,99170,262Mar 15 04:02 PM
Dorling JanetDirectorFeb 12 '24Option Exercise4.636,00027,7806,000Feb 14 06:43 PM
Dorling JanetDirectorFeb 12 '24Sale31.976,000191,8490Feb 14 06:43 PM
McWherter CharlesPresident of R&DJan 19 '24Option Exercise7.0918,403130,52223,334Jan 22 06:59 PM
McWherter CharlesPresident of R&DJan 19 '24Sale23.6718,403435,64515,000Jan 22 06:59 PM
Menold DanielVice President, FinanceJan 16 '24Option Exercise4.0510,00040,50010,000Jan 16 07:07 PM
Quinlan Paul TGeneral CounselJan 16 '24Option Exercise2.945,00014,7005,000Jan 16 07:07 PM
Menold DanielVice President, FinanceJan 16 '24Sale23.5810,000235,8060Jan 16 07:07 PM
Quinlan Paul TGeneral CounselJan 16 '24Sale23.585,000117,8980Jan 16 07:07 PM
Dorling JanetDirectorJan 10 '24Option Exercise4.636,00027,7806,000Jan 10 08:35 PM
Dorling JanetDirectorJan 10 '24Sale23.866,000143,1440Jan 10 08:35 PM
McWherter CharlesPresident of R&DDec 18 '23Option Exercise5.0011,33256,66021,504Dec 18 08:04 PM
McWherter CharlesPresident of R&DDec 18 '23Sale21.4811,332243,44115,000Dec 18 08:04 PM
Menold DanielVice President, FinanceDec 15 '23Option Exercise6.3921,497137,42011,497Dec 15 04:38 PM
Quinlan Paul TGeneral CounselDec 15 '23Option Exercise2.945,00014,7005,000Dec 15 04:35 PM
Menold DanielVice President, FinanceDec 15 '23Sale21.9921,497472,6460Dec 15 04:38 PM
Quinlan Paul TGeneral CounselDec 15 '23Sale21.985,000109,9020Dec 15 04:35 PM
Shah SujalChief Executive OfficerDec 11 '23Option Exercise5.0064,865324,325235,276Dec 11 07:03 PM
Dorling JanetDirectorDec 11 '23Option Exercise4.636,00027,7806,000Dec 11 07:01 PM
Shah SujalChief Executive OfficerDec 11 '23Sale20.0064,8651,297,170171,301Dec 11 07:03 PM
Dorling JanetDirectorDec 11 '23Sale20.076,000120,4220Dec 11 07:01 PM
McWherter CharlesPresident of R&DNov 17 '23Option Exercise5.0011,34256,71026,342Nov 17 05:58 PM
McWherter CharlesPresident of R&DNov 17 '23Sale18.2811,342207,29315,000Nov 17 05:58 PM
Menold DanielVice President, FinanceNov 15 '23Option Exercise3.4517,50060,37517,500Nov 17 05:57 PM
Quinlan Paul TGeneral CounselNov 15 '23Option Exercise2.945,00014,7005,000Nov 17 05:57 PM
Quinlan Paul TGeneral CounselNov 15 '23Sale17.385,00086,8890Nov 17 05:57 PM
McWherter CharlesPresident of R&DOct 18 '23Option Exercise5.0021,743108,71536,743Oct 18 06:22 PM
McWherter CharlesPresident of R&DOct 18 '23Sale14.0721,743305,94115,000Oct 18 06:22 PM
Menold DanielVice President, FinanceOct 16 '23Option Exercise3.4517,50060,37517,500Oct 18 06:22 PM
Quinlan Paul TGeneral CounselOct 16 '23Option Exercise2.945,00014,7005,000Oct 18 06:21 PM
Quinlan Paul TGeneral CounselOct 16 '23Sale13.765,00068,7980Oct 18 06:21 PM
Shah SujalChief Executive OfficerOct 09 '23Option Exercise5.0064,861324,305236,162Oct 10 05:04 PM
Shah SujalChief Executive OfficerOct 09 '23Sale14.2064,861921,286171,301Oct 10 05:04 PM
EMSTER KURT VONDirectorSep 29 '23Option Exercise5.0015,92179,605105,921Sep 29 05:54 PM
EMSTER KURT VONDirectorSep 29 '23Sale15.6815,921249,67590,000Sep 29 05:54 PM
McWherter CharlesPresident of R&DSep 18 '23Option Exercise5.0021,746108,73036,746Sep 19 05:27 PM
McWherter CharlesPresident of R&DSep 18 '23Sale16.2221,746352,73315,000Sep 19 05:27 PM
Quinlan Paul TGeneral CounselSep 15 '23Option Exercise2.9453,000155,82024,000Sep 19 05:23 PM
Menold DanielVice President, FinanceSep 15 '23Option Exercise1.7316,54528,61215,000Sep 19 05:25 PM
Quinlan Paul TGeneral CounselSep 15 '23Sale16.8753,000894,1410Sep 19 05:23 PM
McWherter CharlesPresident of R&DAug 18 '23Option Exercise5.0021,746108,73036,746Aug 18 07:03 PM
McWherter CharlesPresident of R&DAug 18 '23Sale11.4721,746249,35915,000Aug 18 07:03 PM
Menold DanielVice President, FinanceAug 15 '23Option Exercise5.1015,50079,0108,500Aug 16 04:59 PM
Quinlan Paul TGeneral CounselAug 15 '23Option Exercise2.945,00014,7005,000Aug 16 04:57 PM
Quinlan Paul TGeneral CounselAug 15 '23Sale11.915,00059,5500Aug 16 04:57 PM
Menold DanielVice President, FinanceAug 09 '23Option Exercise5.0020,945104,72520,945Aug 11 06:26 PM
Menold DanielVice President, FinanceAug 09 '23Sale12.3520,945258,7440Aug 11 06:26 PM
McWherter CharlesPresident of R&DJul 18 '23Option Exercise5.0021,749108,74536,749Jul 19 06:05 PM
McWherter CharlesPresident of R&DJul 18 '23Sale11.4321,749248,51915,000Jul 19 06:05 PM
Quinlan Paul TGeneral CounselJul 14 '23Option Exercise2.945,00014,7005,000Jul 14 06:52 PM
Quinlan Paul TGeneral CounselJul 14 '23Sale11.815,00059,0500Jul 14 06:52 PM
Quinlan Paul TGeneral CounselJun 30 '23Option Exercise2.945,00014,7005,000Jun 30 04:51 PM
Quinlan Paul TGeneral CounselJun 30 '23Sale10.055,00050,2500Jun 30 04:51 PM
McWherter CharlesPresident of R&DJun 20 '23Option Exercise5.0021,749108,74536,749Jun 21 06:46 PM
McWherter CharlesPresident of R&DJun 20 '23Sale8.1621,749177,38315,000Jun 21 06:46 PM
McWherter CharlesPresident of R&DMay 18 '23Option Exercise5.0021,749108,74536,749May 19 06:00 PM
McWherter CharlesPresident of R&DMay 18 '23Sale9.0821,749197,38715,000May 19 06:00 PM
Quinlan Paul TGeneral CounselMay 15 '23Option Exercise2.945,00014,7005,000May 17 07:11 PM
Quinlan Paul TGeneral CounselMay 15 '23Sale10.375,00051,8310May 17 07:11 PM
KIM DENNIS DChief Medical OfficerApr 17 '23Option Exercise4.37112,219490,397132,219Apr 17 07:24 PM
KIM DENNIS DChief Medical OfficerApr 17 '23Sale9.54112,2191,070,53620,000Apr 17 07:24 PM
KIM DENNIS DChief Medical OfficerApr 13 '23Option Exercise4.377,78134,00327,781Apr 17 07:24 PM
KIM DENNIS DChief Medical OfficerApr 13 '23Sale8.987,78169,88020,000Apr 17 07:24 PM
KIM DENNIS DChief Medical OfficerMar 28 '23Option Exercise4.3710043720,100Mar 30 05:39 PM
KIM DENNIS DChief Medical OfficerMar 28 '23Sale8.9810089820,000Mar 30 05:39 PM